A Phase 3 clinical trial comparing HRS-7535 with dapagliflozin in adult participants with Type 2 Diabetes reached primary completion on 2026-02-18. This study, which enrolled 800 participants, evaluates the efficacy and safety of HRS-7535 against dapagliflozin.
Background
Dapagliflozin is a medication used in the treatment of Type 2 Diabetes. In this particular study, dapagliflozin served as the comparator drug against the investigational agent HRS-7535.
Trial design
The study (NCT06589765) is a Phase 3 trial designed to compare HRS-7535 with dapagliflozin. It enrolled 800 adult participants diagnosed with Type 2 Diabetes who had inadequate glycemic control with metformin. The trial's objective is to evaluate the efficacy and safety of HRS-7535 against dapagliflozin.
What this means
The primary completion of this Phase 3 trial indicates that data collection for the study's primary outcome measures has concluded. The trial aims to provide comparative data on the efficacy and safety of HRS-7535 relative to dapagliflozin in managing Type 2 Diabetes. Future release of the study results will clarify the comparative profile of HRS-7535.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06589765, titled "A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin," was posted on 2026-02-18 on clinicaltrials.gov.